Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies

被引：0
|
作者：
Selmi, Carlo [1 ]
Salaffi, Fausto [2 ]
Aydin, Sibel [3 ]
Soriano, Enrique [4 ,5 ]
Rampakakis, Emmanouil [6 ]
Sharaf, Mohamed [7 ]
Zimmermann, Miriam [8 ]
Lavie, Frederic [9 ]
Nash, Peter [10 ]
Mease, Philip J. [11 ,12 ]
机构：
[1] Humanitas Univ, Humanitas Res Hosp, Rheumatol & Clin Immunol, Internal Med, Rozzano, Italy
[2] Polytech Univ Marche, Carlo Urbani Hosp, Dept Clin & Mol Sci, Ancona, Italy
[3] Ottawa Hosp Riverside Campus, Dept Med, Ottawa, ON, Canada
[4] Hosp Italiano Buenos Aires, Internal Med Serv, Rheumatol Sect, Buenos Aires, DF, Argentina
[5] Univ Inst Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina
[6] McGill Univ, Dept Pediat, Sci Affairs, JSS Med Res, Montreal, PQ, Canada
[7] Janssen MEA, Immunol, Dubai, U Arab Emirates
[8] Janssen Med Affairs LLC, Immunol, Zug, Switzerland
[9] Johnson & Johnson, Janssen Pharmaceut Co, Paris, France
[10] Griffith Univ, Sch Med, Brisbane, Qld, Australia
[11] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[12] Univ Washington, Sch Med, Seattle, WA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1429
引用
收藏
页码：2809 / 2811
页数：3
相关论文
共 50 条
  • [21] The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial
    Ritchlin, Christopher T.
    Coates, Laura C.
    Mease, Philip J.
    van der Heijde, Desiree
    Song, Jiao
    Jiang, Yusang
    Shawi, May
    Kollmeier, Alexa P.
    Rahman, Proton
    TRIALS, 2023, 24 (01)
  • [22] INDIVIDUAL ENTHESEAL POINTS HAVE DIFFERENTIAL FREQUENCY OF INVOLVEMENT AND IMPACT ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED ANALYSIS OF TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES
    Coates, L.
    Mcinnes, I.
    Aydin, S.
    Kishimoto, M.
    Mease, P. J.
    Shawi, M.
    Zimmermann, M.
    Rampakakis, E.
    Lavie, F.
    Mcgonagle, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 220 - 221
  • [23] Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
    Coates, Laura
    McInnes, Iain
    Aydin, Sibel
    Kishimoto, Mitsumasa
    Mease, Philip J.
    Shawi, May
    Zimmermann, Miriam
    Rampakakis, Emmanouil
    Lavie, Frederic
    McGonagle, Dennis
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4398 - 4400
  • [24] SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
    Nielsen, S. Holm
    Bay-Jensen, A. C.
    Frederiksen, P.
    Karsdal, M.
    Shawi, M.
    Chakravarty, S. D.
    Kollmeier, A.
    Chen, W.
    Gao, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 342 - 343
  • [25] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
    Coates, Laura C.
    Rahman, Proton
    Mease, Philip J.
    Shawi, May
    Rampakakis, Emmanouil
    Kollmeier, Alexa P.
    Xu, Xie L.
    Chakravarty, Soumya D.
    McInnes, Iain B.
    Tam, Lai-Shan
    BMC RHEUMATOLOGY, 2024, 8 (01)
  • [26] Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
    Nielsen, Signe Holm
    Bay-Jensen, Anne-Christine
    Frederiksen, Peder
    Karsdal, Morten
    Shawi, May
    Chakravarty, Soumya
    Kollmeier, Alexa
    Chen, Warner
    Gao, Sheng
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4219 - 4220
  • [27] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
    Laura C. Coates
    Proton Rahman
    Philip J. Mease
    May Shawi
    Emmanouil Rampakakis
    Alexa P. Kollmeier
    Xie L. Xu
    Soumya D. Chakravarty
    Iain B. McInnes
    Lai-Shan Tam
    BMC Rheumatology, 8
  • [28] Golimumab 3-Year Safety Update: An Analysis of Pooled Data From the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay, Jonathan
    Fleischmann, Roy
    Keystone, Edward
    Hsia, Elizabeth C.
    Doyle, Mittie K.
    Hsu, Benjamin
    Mack, Michael
    Beutler, Anna
    Braun, Juergen
    Kavanaugh, Arthur
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S870 - S870
  • [29] Efficacy and safety of Guselkumab through 2 years: Results from a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis
    McInnes, I.
    Rahman, P.
    Gottlieb, A.
    Hsia, E.
    Kollmeier, A.
    Xu, X.
    Sheng, S.
    Jiang, Y.
    Shawi, M.
    Chakravarty, S.
    van der Heijde, D.
    Mease, P.
    EXPERIMENTAL DERMATOLOGY, 2021, 30 : 38 - 38
  • [30] Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Kavanaugh, Arthur
    Lam, Gordon
    Tam, Lin-Shan
    Shiff, Natalie
    Lee, Youngja
    Perdomo, Ana-Maria Bravo
    Shawi, May
    Hsia, Elizabeth
    Rampakakis, Emmanouil
    Gutierrez, Carlos Enrique Toro
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4170 - 4172
12345